Resource allocation has significantly transformed in the ever-evolving pharma industry landscape in recent years. Traditionally, pharma companies invested heavily in in-house research and development (R&D) to fuel innovation and bring new drugs to market. However, a noticeable shift has occurred, with a growing trend towards acquiring biotech companies rather than conducting extensive in-house research. This shift has sparked discussions and debates within the industry about its implications and potential consequences.

The pharma industry is vital in the healthcare ecosystem, continuously striving to develop innovative drugs that can improve and save lives. Behind the scenes, a complex web of funding sources contributes to these groundbreaking medications’ research and development (R&D). One often debated aspect is the role of taxpayers in subsidizing drug development. In this blog post, we’ll delve into the intricacies of this issue to better understand the relationship between taxpayers and the pharma research landscape.